MDD drug Brintellix approved in China
The Chinese Food and Drug Administration has approved Brintellix (vortioxetine) for the treatment of major depressive disorders (MDD) in that country.
As a result, the drug’s maker, Denmark based Lundbeck (LUND: CO), has said it expects to start launching Brintellix in China in the second quarter of 2018, and hopes to expand its already leading position in the MDD market there.
Lundbeck is already the market leader in the anti-depressant market in China as around 26% of all medicines prescribed for treating depression in China are invented by Lundbeck. The expected launch of Brintellix will enable Lundbeck to make an even bigger difference for the many patients and caregivers affected by depression in China, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze